Sygnature Discovery

JUNE 17, 2024

Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities. Sygnature Discovery’s Biophysical Assay Development Capabilities: 1.

Biophysical Assays 52

Biophysical Assays Screening Hits Fragment Screening Assay Development 52

Covalent Modifiers

SEPTEMBER 9, 2023

Orthogonal biophysical assays, including mass spectrometry and fluorescence anisotropy, were used to establish structure–activity relationships. Here, we show the structure-based optimization of the nonselective fragment toward selective and highly potent small-molecule stabilizers of the 14-3-3σ/ERα complex.

Small Molecule 75

Small Molecule Biophysical Assays Production Drugs 75

Zobio

DECEMBER 7, 2023

Biochemical assays are commonly used to assess how organic compounds impact the activity of a protein of interest (POI).

Biochemical Assays 52

Biochemical Assays Biophysical Assays Drugs 52

Drug Target Review

NOVEMBER 1, 2023

In 2007 Dr van Montfort joined the Institute of Cancer Research (London, UK), where he holds a joint position between the Centre for Cancer Drug Discovery (CCDD) and the Division of Structural Biology.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Covalent Modifiers

FEBRUARY 1, 2024

Taken together, the protein bioconjugation toolkit that we disclose herein will contribute towards the generation of both mono and multi-labelled protein-small molecule bioconjugates for applications as diverse as biophysical assays, cellular imaging, and the production of therapeutic protein–drug conjugates.

Biophysical Assays 75

Biophysical Assays Small Molecule Drug Development Production 75